| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| A421116-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $121.90 |
TNF-α Selective Inhibitors | Activators | Antagonists
| Synonyms | APX-115 free base | 1270084-92-8 | Isuzinaxib | 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol | Isuzinaxib [INN] | APX-115 (free base) | EWHA-18278 free base | YP664UDC7T | 1-(pyridin-2-yl)-3-phenyl-4-propyl-1H-pyrazol-5-ol | 3-Phenyl-4-propyl-1-(2-pyridinyl)-1H-pyraz |
|---|---|
| Specifications & Purity | Moligand™, 10mM in DMSO |
| Biochemical and Physiological Mechanisms | APX-115 free base (Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses |
| Storage Temp | Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Grade | Moligand™ |
| Product Description | Information APX-115 free base (Ewha-18278 free base) is a potent, orally active inhibitor ofpan NADPH oxidase (pan-Nox)with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules includingMCP-1/CCL2,IL-6, andTNFαin the diabetic kidney. Targets MCP-1/CCL2 ; IL-6 ; TNFα ; NOX2 (Cell-free assay); NOX4 (Cell-free assay) 33094,; 0.57 μM(Ki); 0.63 μM(Ki) |
| ALogP | 2.994 |
|---|---|
| HBD Count | 1 |
| Rotatable Bond | 4 |
| IUPAC Name | 5-phenyl-4-propyl-2-pyridin-2-yl-1H-pyrazol-3-one |
|---|---|
| INCHI | InChI=1S/C17H17N3O/c1-2-8-14-16(13-9-4-3-5-10-13)19-20(17(14)21)15-11-6-7-12-18-15/h3-7,9-12,19H,2,8H2,1H3 |
| InChi Key | GIWZEELPLKPYBA-UHFFFAOYSA-N |
| Canonical SMILES | CCCC1=C(NN(C1=O)C2=CC=CC=N2)C3=CC=CC=C3 |
| Isomeric SMILES | CCCC1=C(NN(C1=O)C2=CC=CC=N2)C3=CC=CC=C3 |
| PubChem CID | 51036475 |
| Molecular Weight | 279.34 |
